title: Properties of blebbistatin for cardiac optical mapping and other imaging applications.
abstract: Blebbistatin is a recently discovered myosin II inhibitor. It is rapidly becoming a compound of choice to reduce motion artifacts during cardiac optical mapping, as well as to study cell motility and cell invasion. Although blebbistatin has a number of advantages over other electromechanical uncouplers, many of its properties have yet to be addressed. Here we describe several methodological issues associated with the use of blebbistatin, including its spectral properties, reversibility, and its effect on tissue metabolic state. We show that if precautions are not taken, perfusion with blebbistatin may result in blebbistatin precipitate that accumulates in the vasculature. Although such precipitate is fluorescent, it is not detectable within wavelength bands that are typically used for transmembrane voltage fluorescence imaging (i.e., emission wavelengths >600 nm). Therefore, blockage of the microcirculation by blebbistatin may cause data misinterpretation in studies that use voltage-sensitive dyes. Blebbistatin may also impact imaging of green fluorophores due to the spectral shift it causes in endogenous tissue fluorescence. 3D excitation-emission matrices of blebbistatin in precipitate form and in various solutions (DMSO, water, and 1 % aqueous albumin) revealed significant changes in the fluorescence of this molecule in different environments. Finally, we examined the reversibility of blebbistatin's uncoupling effect on cardiac contraction. Our findings provide important new information about the properties of this myosin II inhibitor, which will aid in the proper design and interpretation of studies that use this compound.
authors.affiliation: Department of Pharmacology and Physiology, The George Washington University Medical Center, 2300 Eye Street, Washington, DC 20037, USA.
authors.forename: Luther M
authors.initials: LM
authors.lastname: Swift
authors.forename: Huda
authors.initials: H
authors.lastname: Asfour
authors.forename: Nikki G
authors.initials: NG
authors.lastname: Posnack
authors.forename: Ara
authors.initials: A
authors.lastname: Arutunyan
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Kay
authors.forename: Narine
authors.initials: N
authors.lastname: Sarvazyan
mesh_terms: D000818:Animals; D056149:Epicardial Mapping / Q000379:methods*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000737:chemistry / Q000494:pharmacology*; D066298:In Vitro Techniques; D055414:Myocardial Perfusion Imaging / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D056969:Voltage-Sensitive Dye Imaging / Q000379:methods*
chemical_list: D006576:Heterocyclic Compounds, 4 or More Rings; C472645:blebbistatin